FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898544252> ?p ?o ?g. }

• W2898544252 endingPage "413" @default.
• W2898544252 startingPage "407" @default.
• W2898544252 abstract "Objective To describe the clinical outcomes associated with the use of checkpoint inhibitor therapy in recurrent ovarian malignancy. Methods Women with recurrent ovarian cancer treated with an immune checkpoint inhibitor between 1/2012 and 8/2017 were included. RECIST criteria determined disease status, and immune related adverse events (irAE) were graded per trial protocols. Predictors of response, irAE, progression free survival (PFS) and overall survival (OS) were investigated. Results Forty-four women were included with a median age of 53 years, median of 4 prior lines of chemotherapy, and most commonly high grade serous pathology (59.1%). 3 patients had partial response and 3 had pseudoprogression, for a response rate of 14.2%. In subset analysis of high grade serous (HGSOC) pathology, platinum sensitivity at time of checkpoint inhibitor therapy was correlated with response (p = 0.01). There were 28 grade 3/4 irAEs in 21 patients (47.7%). Combination therapy rather than monotherapy predicted irAE (OR 5.7, CI 1.6–20.9, p = 0.02). The most common severe irAE was elevation in hepatic or pancreatic enzymes in 12 total patients (13.6% each). Interestingly, the number of genes mutated was protective from hepatic/pancreatic AE (p = 0.02). Conclusions While response rate was similar to prior literature, in patients with HGSOC platinum sensitivity at time of checkpoint inhibitor initiation was correlated to response. Grade 3/4 hepatic and pancreatic enzyme elevations were more common in ovarian cancer patients than has been previously reported in other tumor types. The number of genes mutated was inversely correlated to risk of this type of irAEs but not to total irAEs." @default.
• W2898544252 created "2018-11-02" @default.
• W2898544252 creator A5000158770 @default.
• W2898544252 creator A5005436649 @default.
• W2898544252 creator A5008222365 @default.
• W2898544252 creator A5026095888 @default.
• W2898544252 creator A5033579945 @default.
• W2898544252 creator A5033798832 @default.
• W2898544252 creator A5049857815 @default.
• W2898544252 creator A5057775466 @default.
• W2898544252 date "2018-12-01" @default.
• W2898544252 modified "2023-10-14" @default.
• W2898544252 title "Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials" @default.
• W2898544252 cites W1759669640 @default.
• W2898544252 cites W1982488143 @default.
• W2898544252 cites W1984642649 @default.
• W2898544252 cites W2006122393 @default.
• W2898544252 cites W2019607817 @default.
• W2898544252 cites W2021382013 @default.
• W2898544252 cites W2052702202 @default.
• W2898544252 cites W2060070314 @default.
• W2898544252 cites W2100158834 @default.
• W2898544252 cites W2101653483 @default.
• W2898544252 cites W2105057287 @default.
• W2898544252 cites W2123696077 @default.
• W2898544252 cites W2136313650 @default.
• W2898544252 cites W2137074525 @default.
• W2898544252 cites W2147622445 @default.
• W2898544252 cites W2152897456 @default.
• W2898544252 cites W2153942285 @default.
• W2898544252 cites W2179179825 @default.
• W2898544252 cites W2314266201 @default.
• W2898544252 cites W2336303313 @default.
• W2898544252 cites W2345415641 @default.
• W2898544252 cites W2509217584 @default.
• W2898544252 cites W2519279652 @default.
• W2898544252 cites W2560367415 @default.
• W2898544252 cites W2572174216 @default.
• W2898544252 cites W2592692971 @default.
• W2898544252 cites W2593599476 @default.
• W2898544252 cites W2594042408 @default.
• W2898544252 cites W2746357202 @default.
• W2898544252 cites W2753432434 @default.
• W2898544252 cites W2765763462 @default.
• W2898544252 cites W2784920809 @default.
• W2898544252 cites W2789465165 @default.
• W2898544252 cites W2793180707 @default.
• W2898544252 cites W2794538118 @default.
• W2898544252 cites W2804569878 @default.
• W2898544252 cites W2892169873 @default.
• W2898544252 cites W2918892827 @default.
• W2898544252 cites W4376453126 @default.
• W2898544252 doi "https://doi.org/10.1016/j.ygyno.2018.10.008" @default.
• W2898544252 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6281778" @default.
• W2898544252 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30366646" @default.
• W2898544252 hasPublicationYear "2018" @default.
• W2898544252 type Work @default.
• W2898544252 sameAs 2898544252 @default.
• W2898544252 citedByCount "16" @default.
• W2898544252 countsByYear W28985442522019 @default.
• W2898544252 countsByYear W28985442522020 @default.
• W2898544252 countsByYear W28985442522021 @default.
• W2898544252 countsByYear W28985442522022 @default.
• W2898544252 countsByYear W28985442522023 @default.
• W2898544252 crossrefType "journal-article" @default.
• W2898544252 hasAuthorship W2898544252A5000158770 @default.
• W2898544252 hasAuthorship W2898544252A5005436649 @default.
• W2898544252 hasAuthorship W2898544252A5008222365 @default.
• W2898544252 hasAuthorship W2898544252A5026095888 @default.
• W2898544252 hasAuthorship W2898544252A5033579945 @default.
• W2898544252 hasAuthorship W2898544252A5033798832 @default.
• W2898544252 hasAuthorship W2898544252A5049857815 @default.
• W2898544252 hasAuthorship W2898544252A5057775466 @default.
• W2898544252 hasBestOaLocation W28985442522 @default.
• W2898544252 hasConcept C121608353 @default.
• W2898544252 hasConcept C126322002 @default.
• W2898544252 hasConcept C143998085 @default.
• W2898544252 hasConcept C150173356 @default.
• W2898544252 hasConcept C197934379 @default.
• W2898544252 hasConcept C2776694085 @default.
• W2898544252 hasConcept C2778822529 @default.
• W2898544252 hasConcept C2779399171 @default.
• W2898544252 hasConcept C2779984678 @default.
• W2898544252 hasConcept C2780210213 @default.
• W2898544252 hasConcept C2780427987 @default.
• W2898544252 hasConcept C2780739268 @default.
• W2898544252 hasConcept C535046627 @default.
• W2898544252 hasConcept C71924100 @default.
• W2898544252 hasConcept C90924648 @default.
• W2898544252 hasConceptScore W2898544252C121608353 @default.
• W2898544252 hasConceptScore W2898544252C126322002 @default.
• W2898544252 hasConceptScore W2898544252C143998085 @default.
• W2898544252 hasConceptScore W2898544252C150173356 @default.
• W2898544252 hasConceptScore W2898544252C197934379 @default.
• W2898544252 hasConceptScore W2898544252C2776694085 @default.
• W2898544252 hasConceptScore W2898544252C2778822529 @default.
• W2898544252 hasConceptScore W2898544252C2779399171 @default.
• W2898544252 hasConceptScore W2898544252C2779984678 @default.

• next